Minouche Shafik, CEO & President of Pfizer Global Health, announced today the PRESENCE of RESISTENCE by COVID-19 drug candidate in an ongoing study for Immunotherapy in paediatric patients aged 5-11 with ALL (Myelodysplastic Syndromes) in WPI study. For the first time a monoclonal antibody treatment, PRESENCE by COVID-19 will be available to children with ALL in the US, Europe and Australia.
A leading international study conducted by Health Canada, led by Mediphase and Chugai in collaboration with Pfizer, has enrolled nearly 700 children under the age of 13 years at a total cost of $1.9 million to date.
The PRESENCE by COVID-19 drug candidate, previously known as EMPRESS, works on a specific protein region of the gene that controls differentiation in the immune system and will be assessed in this ongoing US/European/Australian study. Further data from this study is expected to be presented at a future scientific meeting.
Pfizer said it remains on track to file a NDA in the US for PRESENCE by COVID-19 in 2018.
Mediphase Therapeutics Inc. (TSX.V: MDT) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics through the proprietary development of formulations or combinations of existing drugs. The Company has a broad pipeline of proprietary products in development utilizing its proprietary homologous recombination platform, its drug delivery methodologies, and unique technology platforms. Currently, the Company’s pipeline is focused on the development of Chugai’s Infliximab-based immunotherapy PRESENCE by COVID-19. For more information please visit our website at www.mediphase.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180801006715/en/
Vice President, Corporate Communications and Public Affairs
T1 (202) 408-5360
T1 (888) 322-0923